VCM
EBS icon

Voleon Capital Management’s Emergent Biosolutions EBS Stock Holding History

Voleon Capital Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-30,000
Closed -$1.57M – 205
2019
Q3 		$1.57M Buy
+30,000
New +$1.4M 0.12% 110

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Voleon Capital Management's EBS Position: Q4 2019 in Review

Voleon Capital Management sold out of Emergent Biosolutions (EBS) in Q4 2019, closing a stake of 30,000 shares — an estimated $1.57M sold.

Voleon Capital Management first reported a position in EBS in Q3 2019 and held it in 1 quarter. The position peaked at $1.57M in Q3 2019. 236 funds tracked by Wall St. Rank hold EBS as of Q4 2019.

  • Voleon Capital Management reported no remaining Emergent Biosolutions position as of Q4 2019 after selling out during the quarter.
  • Voleon Capital Management sold 30,000 Emergent Biosolutions shares in Q4 2019, an estimated $1.57M.
  • Voleon Capital Management first reported a position in Emergent Biosolutions in Q3 2019 and held it in 1 quarter.
  • Voleon Capital Management's Emergent Biosolutions position peaked at $1.57M in Q3 2019.
  • 236 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2019.

Based on Voleon Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.